Sugi Predict

Sugi Predict / Targets / CYSLTR2

CYSLTR2

Cysteinyl leukotriene receptor 2 · Q9NS75 · CYSLTR2 on Sugi Atlas →

55,408 patent compounds predicted against CYSLTR2, 31,104 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Gemilukast Gemilukast (SCHEMBL597344) 1.00 20/20
SCHEMBL597729 SCHEMBL597729 1.00 20/20
SCHEMBL598035 SCHEMBL598035 1.00 20/20
SCHEMBL598080 SCHEMBL598080 1.00 20/20
SCHEMBL598227 SCHEMBL598227 1.00 20/20
SCHEMBL598228 SCHEMBL598228 1.00 20/20
SCHEMBL598562 SCHEMBL598562 1.00 20/20
SCHEMBL598642 SCHEMBL598642 1.00 20/20
SCHEMBL599234 SCHEMBL599234 1.00 20/20
SCHEMBL599235 SCHEMBL599235 1.00 20/20
SCHEMBL597788 SCHEMBL597788 0.89 20/20
SCHEMBL597067 SCHEMBL597067 0.88 20/20
SCHEMBL597491 SCHEMBL597491 0.86 20/20
Gemilukast Gemilukast (SCHEMBL597425) 0.86 20/20
SCHEMBL598258 SCHEMBL598258 0.85 20/20
SCHEMBL598098 SCHEMBL598098 0.85 20/20
SCHEMBL599253 SCHEMBL599253 0.85 20/20
Gemilukast Gemilukast (SCHEMBL598116) 0.84 20/20
Water Water (SCHEMBL597526) 0.84 20/20
Gemilukast Gemilukast (SCHEMBL597080) 0.83 20/20

Clinical trials — most relevant to CYSLTR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Open-label Study of the Effects of Montelukast in Patients With Chronic Cough PHASE4COMPLETED
Effect of Montelukast on the Airway Remodeling PHASE4COMPLETED
Investigation to Identify Predictors of Response to a Treatment With Montelukast PHASE4COMPLETED
Exercise Induced Bronchospasm in Children PHASE4COMPLETED
Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children PHASE4COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Wheeze and Intermittent Treatment PHASE3COMPLETED
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps PHASE3ACTIVE_NOT_RECRUITING
Aspirin for Uncontrolled Asthma PHASE3COMPLETED
Predicting the Response to Montelukast by Genetic Variation in Asthmatics PHASE3COMPLETED
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
GSK2190915 Neutrophilic Asthma Study PHASE2COMPLETED
Treatment of Bronchial Asthma With Borage and Echium Seed Oils PHASE1/PHASE2COMPLETED
Treating Exacerbations of Asthma With Oral Montelukast in Children PHASE2COMPLETED
Investigation the Effect of Montelukast in COVID-19 PHASE2UNKNOWN
Montelukast Therapy on Alzheimer's Disease PHASE2COMPLETED
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial) EARLY_PHASE1RECRUITING
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers EARLY_PHASE1UNKNOWN
CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis nanUNKNOWN
Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing nanUNKNOWN
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma nanCOMPLETED
A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma nanUNKNOWN
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial nanCOMPLETED
Gender Differences and SNPs in Asthmatic Patients nanUNKNOWN
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT nanCOMPLETED
Montelukast in the Treatment of Duodenal Eosinophilia nanCOMPLETED
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma nanCOMPLETED
Transporter Mediated Uptake of Montelukast nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYSLTR2 binder may also engage these)

ProteinNameSimilarity
Q95N03 — 0.997 Q95N03 →
Q3U507 — 0.993 Q3U507 →
GPR174 Probable G-protein coupled receptor 174 0.992 landscape →
Q95N02 — 0.991 Q95N02 →
Q924T8 — 0.990 Q924T8 →
B0UXR0 — 0.990 B0UXR0 →
D4A7K7 — 0.989 D4A7K7 →
Q9XSD4 — 0.989 Q9XSD4 →
Q924T9 — 0.989 Q924T9 →
Q920A1 — 0.988 Q920A1 →
Q3U6B2 — 0.987 Q3U6B2 →
A5PLE7 — 0.987 A5PLE7 →
GPR183 G-protein coupled receptor 183 0.987 landscape →
B5X337 — 0.987 B5X337 →
Q99JA4 — 0.987 Q99JA4 →
P49650 — 0.986 P49650 →
P48042 — 0.986 P48042 →
Q8C131 — 0.986 Q8C131 →
Q61038 — 0.985 Q61038 →
Q9R1K6 — 0.985 Q9R1K6 →
Q2NNR5 — 0.985 Q2NNR5 →
P49651 — 0.985 P49651 →
Q80Z39 — 0.985 Q80Z39 →
Q920E1 — 0.984 Q920E1 →
P2RY10 Putative P2Y purinoceptor 10 0.984 landscape →
Q1RMI1 — 0.984 Q1RMI1 →
CYSLTR1 Cysteinyl leukotriene receptor 1 0.984 landscape →
Q3UJF0 — 0.984 Q3UJF0 →
Q6IYF8 — 0.984 Q6IYF8 →
Q99MT6 — 0.984 Q99MT6 →